Finerenone Cardiorenal Effects in T2D Consistent Across Baseline HbA1c, Disease Duration
ADA 2022: The protective effect of finerenone on cardiovascular and renal outcomes was not affected by initial HbA1c levels or T2D duration in analysis of data from the FIDELITY pooled cohort.
CDC Elevates Monkeypox Alert to Level 2, Encourages "Enhanced Precautions"
The CDC raised its monkeypox alert to a level 2 on June 6, reporting more than 1000 cases worldwide and 25 infections confirmed in 12 US states and DC.
Kidney Outcomes with Tirzepatide in T2D: Hiddo Heerspink, PhD, PharmD Highlights SURPASS-4 Analysis
ADA 2022: Professor Hiddo Heerspink led the prespecified SURPASS-4 analysis that found tirzepatide associated with a 41% reduction in risk of a composite renal outcome.
Empagliflozin More Effective to Reduce Risk of Heart Failure Hospitalization vs DPP-4 Inhibitors, GLP-1 Receptor Agonists
ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of June 6, 2022
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
Younger Age and Higher HbA1c Among Factors Linked to CGM Uptake in New Study
ADA 2022: Younger age, insulin use, higher HbA1c, and higher diabetes distress were found to be associated with CGM uptake in prospective study.
Patients with Diabetes Up to 4-times More Likely to Develop Long COVID-19
ADA 2022: In a new literature review, 43% of studies included identified diabetes as a potent risk for developing post-acute sequelae of COVID-19.
Tirzepatide Treatment Leads to Weight Loss of up to 22.5% in SURMOUNT-1 Clinical Trial
ADA 2022: Tirzepatide led overall to weight loss of up to 22.5% of baseline body weight with persons taking the 15 mg dose losing an average of 52 pounds.
Tirzepatide Slows Renal Decline in T2D Patients with CKD in First Analysis of Dual Agent on Kidney Function
ADA 2022: Tirzepatide, a GIP/GLP-1 receptor agonist, reduced a composite of kidney events in patients with type 2 diabetes and at increased cardiovascular risk in an analysis of SURPASS-4.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of June 3, 2022
Obesity and Depression in Adolescents: Understanding the Interplay
Understanding the interplay between obesity and depression in children is key for clinicians to best advise this patient population. An overview, here.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of June 2, 2022
Seen in the ED: Heroin OD
A man of about 40-years-old is seen in the ED for a possible drug overdose. He complains of low back pain and asks for medication. What's your diagnosis?
CGM News: FreeStyle Libre 3 Cleared by FDA for Persons Aged 4 Years and Older with Diabetes
The Abbott FreeStyle Libre 3 is the smallest, thinnest, and most accurate 14-day CGM with a 7.9% MARD, the company says.
Gen Z Youth Want Their Physicians to Ask Them about Social Determinants of Health
A new survey of youth aged 14 to 24 years provides significant support for integrating questions about social needs into routine clinical care.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of June 1, 2022
Heavy Alcohol Use Strongly Associated with Risk of Early-onset Colorectal Cancer, Study Finds
New research shows excessive alcohol use is strongly associated with an increased risk for colorectal cancer, regardless of genetic risk.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of May 31, 2022
Time to Benefit Following Intensive BP Reduction in Adults Aged 60 Years and Older
The first study of its kind found that intensive blood pressure control may be most beneficial in older adults with life expectancy greater than 3 years vs less than 1 year.
Treatment Gap: In Patients with ASCVD, Low Use of Statins, High-intensity Statins Persists
One-half of more than 600 000 patients with ASCVD were not prescribed statins at all and only 22.5% were taking a high intensity statin, according to a recent study.
